Literature DB >> 9300660

Genetics of Parkinson's disease.

R L Nussbaum1, M H Polymeropoulos.   

Abstract

For the past 40 years, research into Parkinson's disease (PD) has been predominantly the province of epidemiologists interested in pursuing the connection between the disease and environmental factors such as viral infection or neurotoxins. Hereditary influences were actually discounted because of a high monozygotic twin discordance rate found in studies that were later shown to be inadequate and inconclusive. There has recently been a resurgence of interest in investigating hereditary factors in PD when it became more and more apparent that a positive family history was a major risk factor for the disease. Meanwhile, it also became increasingly apparent from neuropathological studies that the common, idiopathic form of Parkinson's disease had, in fact, a pathological correlate, i.e., the existence of Lewy bodies, an eosinophilic cytoplasmic inclusion body, distributed diffusely throughout the substantia nigra, hypothalamus, hippocampus, autonomic ganglia and olfactory tracts. Although candidate gene approaches to linkage in PD families have not been rewarding, a genome wide scan mapped PD to 4q21-23 in one large family with PD with diffuse Lewy bodies, where a candidate gene, alpha-synuclein, resides. This gene encodes a presynaptic protein of which a peptide fragment is known to be a constituent of Alzheimer's disease plaques. The identification of a missense mutation in the alpha-synuclein gene in four independent PD families suggests that at least some fraction of familial PD with diffuse Lewy bodies is the result of an abnormal protein that interferes with normal protein degradation leading to the development of inclusions and ultimately neuronal cell death. There may be common pathogenetic mechanisms involved in alpha-synuclein mutations in PD and beta-amyloid and presenilin gene mutations in Alzheimer's disease.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9300660     DOI: 10.1093/hmg/6.10.1687

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  39 in total

Review 1.  Nanotools for megaproblems: probing protein misfolding diseases using nanomedicine modus operandi.

Authors:  Vladimir N Uversky; Alexander V Kabanov; Yuri L Lyubchenko
Journal:  J Proteome Res       Date:  2006-10       Impact factor: 4.466

2.  Response to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) differs in mouse strains and reveals a divergence in JNK signaling and COX-2 induction prior to loss of neurons in the substantia nigra pars compacta.

Authors:  Justin D Boyd; Haeman Jang; Kennie R Shepherd; Ciaran Faherty; Sally Slack; Yun Jiao; Richard J Smeyne
Journal:  Brain Res       Date:  2007-08-09       Impact factor: 3.252

3.  A novel "molecular tweezer" inhibitor of α-synuclein neurotoxicity in vitro and in vivo.

Authors:  Shubhangi Prabhudesai; Sharmistha Sinha; Aida Attar; Aswani Kotagiri; Arthur G Fitzmaurice; Rajeswari Lakshmanan; Ravi Lakshmanan; Magdalena I Ivanova; Joseph A Loo; Frank-Gerrit Klärner; Thomas Schrader; Mark Stahl; Gal Bitan; Jeff M Bronstein
Journal:  Neurotherapeutics       Date:  2012-04       Impact factor: 7.620

4.  Transcriptome Profile Changes in Mice with MPTP-Induced Early Stages of Parkinson's Disease.

Authors:  Anelya Kh Alieva; Elena V Filatova; Anna A Kolacheva; Margarita M Rudenok; Petr A Slominsky; Mikhail V Ugrumov; Maria I Shadrina
Journal:  Mol Neurobiol       Date:  2016-10-18       Impact factor: 5.590

Review 5.  Alpha-synuclein and intracellular trafficking: impact on the spreading of Parkinson's disease pathology.

Authors:  Sibylle E Eisbach; Tiago F Outeiro
Journal:  J Mol Med (Berl)       Date:  2013-04-25       Impact factor: 4.599

Review 6.  MicroRNA implications across neurodevelopment and neuropathology.

Authors:  Sabata Martino; Ilaria di Girolamo; Antonio Orlacchio; Alessandro Datti; Aldo Orlacchio
Journal:  J Biomed Biotechnol       Date:  2009-10-13

7.  Alpha-synuclein disrupted dopamine homeostasis leads to dopaminergic neuron degeneration in Caenorhabditis elegans.

Authors:  Pengxiu Cao; Yiyuan Yuan; Elizabeth A Pehek; Alex R Moise; Ying Huang; Krzysztof Palczewski; Zhaoyang Feng
Journal:  PLoS One       Date:  2010-02-19       Impact factor: 3.240

8.  The WD40 domain is required for LRRK2 neurotoxicity.

Authors:  Nathan D Jorgensen; Yong Peng; Cherry C-Y Ho; Hardy J Rideout; Donald Petrey; Peng Liu; William T Dauer
Journal:  PLoS One       Date:  2009-12-24       Impact factor: 3.240

9.  Merging mouse transcriptome analyses with Parkinson's disease linkage studies.

Authors:  Daniel Gherbassi; Lavinia Bhatt; Sandrine Thuret; Horst H Simon
Journal:  DNA Res       Date:  2007-05-23       Impact factor: 4.458

10.  Drug Targeting of alpha-Synuclein Oligomerization in Synucleinopathies.

Authors:  Tiago Fleming Outeiro; Aleksey Kazantsev
Journal:  Perspect Medicin Chem       Date:  2008-04-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.